The funding measure aims to strengthen the clinical development of promising therapeutic approaches against COVID-19. In this way, preclinically successfully tested candidates for new therapeutics should reach patients as quickly as possible and the treatment repertoire against COVID-19 should be expanded as needed. The purpose of the funding is the clinical development of drug candidates that are explicitly directed against SARS-CoV-2. Further information and contact details of the project executing organization can be found at: www.gesundheitsforschung-bmbf.de/de/12638.php.
Applications for funding can be submitted from now until February 17, 2021. The application process is single-stage.
A virtual information event will be held on February 01, 2021. Further information and the possibility to register can be found on the following website: https://vdivde-it.de/de/veranstaltung/informationsveranstaltung-bmbf-covid-19-therapeutika.
